Chong Kun Dang 
Welcome,         Profile    Billing    Logout  
 53 Products   83 Diseases  53 Products   41 Trials   1724 News 
88 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beloranib (ZGN-440) / Larimar Therap
2015-000660-33: A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placebo

 
3
25
Europe
Subcutaneous Beloranib in Suspension, ZGN-440,
Zafgen Inc., Zafgen Inc.
Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
 
 
Duvie (lobeglitazone) / Chong Kun Dang
NCT02315287: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

Recruiting
4
190
RoW
Pioglitazone, Actos, Lobeglitazone, Duvie
Seoul National University Bundang Hospital
Type 2 Diabetes
12/21
12/21
Location-F, NCT05915949: Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

Recruiting
4
99
RoW
Dapagliflozin 10mg Tab, Forxiga 10mg, Lobeglitazone 0.5 mg, Duvie 0.5 mg, Dapagliflozin + Lobeglitazone, Forxiga 10mg + Duvie 0.5mg
Seoul National University Bundang Hospital
Diabetes Type 2
10/23
12/23
NCT03641352: The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Recruiting
3
240
RoW
CKD-501 0.5mg, Lobeglitazone, Placebo
Chong Kun Dang Pharmaceutical
Type2 Diabetes
04/21
11/22
NCT03627182: Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Recruiting
3
240
RoW
CKD-501 0.5mg, Lobeglitazone 0.5mg, Placebo
Chong Kun Dang Pharmaceutical
Type2 Diabetes
03/22
02/23
NCT04706286: Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

Not yet recruiting
1
26
RoW
CKD-501, D759, D150, Treatment A, CKD-393 0.5/100/1000 mg, Treatment B
Chong Kun Dang Pharmaceutical
T2DM (Type 2 Diabetes Mellitus)
03/21
04/21
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Completed
1
33
RoW
CKD-393, CKD-501, D759, H053
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
12/21
12/21
NCT05816759: Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Completed
1
32
RoW
CKD-383, CKD-501, D744, D150
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
06/23
06/23
NCT05897216: Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

Completed
1
30
RoW
CKD-383, CKD-501, D745, D150, D029
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
07/23
08/23
NCT06483243: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Completed
1
45
RoW
Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG, Test: CKD-383, Reference1: CKD-501, Reference2: D745, Reference3: D150
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
04/24
05/24
NCT06492655: To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

Not yet recruiting
1
28
NA
CKD-383(Fed), Lobeglitazone, Empagliflozin, Metformin, CKD-383(Fasted)
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
08/24
08/24
Tedopi (OSE 2101) / OSE Immunotherapeutics
ATALANTE 1, NCT02654587 / 2015-003183-36: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated
3
219
Europe, US, RoW
OSE2101, TEDOPI, EP-2101, EP2101, IDM-2101, Docetaxel, Taxotere, Pemetrexed, Alimta
OSE Immunotherapeutics, OSE Immunotherapeutics, OSE Pharma
Non Small Cell Lung Cancer
01/21
01/21
ARTEMIA, NCT06472245: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Recruiting
3
363
Europe, Canada, US
OSE2101, Docetaxel, NGS HLAA2 assay
OSE Immunotherapeutics, Exystat, Genome Diagnostics (GenDx)
Patients With Non-Small Cell Lung Cancer
12/27
12/28
2017-004548-40: Phase II randomized of Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with pancreatic carcinoma

Not yet recruiting
2
156
Europe
TEDOPI, nivolumab, OSE2101, Emulsion and suspension for emulsion for injection, Solution for infusion, OPDIVO
GERCOR, OSE IMMUNOTHERAPEUTICS - SA, Bristol Myers Squibb
Locally advanced or metastatic Pancreatic ductal adenocarcinoma, metastatic Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Recruiting
2
105
Europe
Tedopi, Nivolumab, Docetaxel
Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics
Metastatic Non Small Cell Lung Cancer
10/23
05/25
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
2
106
Europe
FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi
GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
12/23
12/24
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
Antiferon (interferon alpha kinoid) / Neovacs
ChiCTR2000035633: Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK/PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients

Not yet recruiting
N/A
32
 
Atomization treatment, 0.2mg IFN-k/ 0.5 mg TFF2 ;Atomization treatment, 1mg IFN-k/ 2.5 mg TFF2 ;Atomization treatment, 2mg IFN-κ/ 5 mg TFF2 ;Atomization treatment, 4mg IFN-κ/ 10 mg TFF2
Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Shanghai Public Health Clinical Center
Novel Coronavirus Pneumonia (COVID-19)
 
 
namodenoson (CF102) / Can-Fite
2021-005286-41: Clinical trial in patients with Advanced Hepatocellular Carcinoma and Child Pugh Class B7 cirrhosis. Клинично изпитване при пациенти с с авансирал хепатоцелуларен карцином с Child-Pugh цироза клас Б7

Ongoing
3
471
Europe
CF102, CF102, Capsule
CanFite BioPharma Ltd., CanFite BioPharma Ltd.
Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis Авансирал хепатоцелуларен карцином с Child-Pugh цироза клас В7, Liver cancer Чернодробен карцином, Diseases [C] - Cancer [C04]
 
 
LIVERATION, NCT05201404 / 2021-005286-41: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Recruiting
3
471
Europe, US, RoW
Namodenoson, CF102, Placebo, Inactive control
Can-Fite BioPharma, CanFite BioPharma Ltd.
Hepatocellular Carcinoma, Cirrhosis
02/26
10/26
CF102-222PC, NCT06387342: Namodenoson Treatment of Advanced Pancreatic Cancer

Recruiting
2
20
RoW
Namodenoson 25mg, CF102
Can-Fite BioPharma
Pancreatic Adenocarcinoma, Pancreatic Cancer
07/26
12/26
NCT04697810 / 2021-005245-32: Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Recruiting
2
114
Europe, RoW
Namodenoson, CF102, Placebo, Inactive control
Can-Fite BioPharma, CanFite BioPharma Ltd.
NASH - Nonalcoholic Steatohepatitis
04/25
10/25
Korsuva IV (difelikefalin IV) / Maruishi Pharma, CSL Behring
NCT04711603: A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Completed
3
178
Japan
MR13A9, Placebo
Kissei Pharmaceutical Co., Ltd.
Uremic Pruritus
01/22
09/22
NCT05885737: Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Completed
3
184
RoW
Difelikefalin Injection, Placebo Injection
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Uremic Pruritus
09/24
09/24
2021-000894-94: Single dose study to evaluate how intravenous administered difelikefalin is absorbed by and cleared from Adolescents on Haemodialysis Studio a dose singola per valutare come difelikefalin somministrato per via endovenosa viene assorbito ed eliminato dagli adolescenti in emodialisi

Ongoing
2
6
Europe
Difelikefalin, [CR845], Solution for infusion
Vifor Fresenius Medical Care Renal Pharma Ltd., Vifor Fresenius Medical Care Renal Pharma Ltd.
Renal disease in the final stage Nefropatia allo stadio terminale, Renal disease in the final stage Malattia renale allo stadio terminale, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
NCT05885763: Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis

Completed
1
30
RoW
Difelikefalin Injection
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
End Stage Renal Disease on Hemodialysis
10/23
10/23
alteminostat (CKD-581) / Chong Kun Dang
NCT03051841: CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Recruiting
1
18
RoW
CKD-581, CKD-581 bortezomib dexamethasone regimen
Chong Kun Dang Pharmaceutical
Myeloma, Multiple
04/21
11/22
valecobulin (CKD-516) / Chong Kun Dang
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Terminated
1/2
25
RoW
CKD-516 plus Durvalumab, CKD-516 plus MEDI4736
Tae Won Kim
Colorectal Cancer, Solid Tumor
03/23
03/23
leuprorelin (CKD-841) / Chong Kun Dang
NCT04840745: The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

Not yet recruiting
1
32
RoW
CKD-841 A-1 3.75mg, CKD-841, CKD-841 A-1 1.88mg, CKD-841 D 2.92mg, Leuplin Inj. 3.75 mg, Leuplin.Inj
Chong Kun Dang Pharmaceutical, Severance Hospital
Early Puberty
10/21
11/21
Telmunivo (s-amlidioine / telmisartan) / Chong Kun Dang
CKD-348, NCT04660370: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of

Completed
1
70
RoW
CKD-348, CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
02/21
04/21
NCT04883658: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Completed
1
62
RoW
CKD-348(2), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
07/21
08/21
NCT05192356: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Completed
1
63
RoW
CKD-348(3), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
05/22
06/22
NCT05549401: Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Completed
1
32
RoW
CKD-348(4) F1, CKD-348(4) F2, CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
11/22
12/22
NCT05749861: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Completed
1
65
RoW
CKD-348(5), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
06/23
07/23
NCT05834595: A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828

Completed
1
43
RoW
CKD-828, D064, D701
Chong Kun Dang Pharmaceutical
Hypertension
07/23
07/23
NCT05881707: A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg

Completed
1
44
RoW
CKD-828, D064, D702
Chong Kun Dang Pharmaceutical
Hypertension
09/23
09/23
NCT06112678: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Completed
1
63
RoW
CKD-348(6), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension, Dyslipidemias
02/24
03/24
CKD-506 / Chong Kun Dang
2018-001377-24: Not available.

Not yet recruiting
2
120
RoW
CKD-506, Tablet
Chong Kun Dang Pharmaceutical Corporation (CKD), Chong Kun Dang Pharmaceutical Corporation (CKD)
Rheumatoid arthritis (RA), Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
Korsuva oral (difelikefalin oral) / CSL Behring
2022-000149-34: A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extension

Not yet recruiting
3
400
Europe, RoW
Difelikefalin, CR845, Tablet
Cara Therapeutics, Inc., Cara Therapeutics, Inc,, Cara Therapeutics, Inc.
Chronic Kidney Disease, Chronic Kidney Disease, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05342623: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Checkmark Trial initiation in non-hemodialysis CKD-aP patients
Apr 2022 - Apr 2022: Trial initiation in non-hemodialysis CKD-aP patients
Terminated
3
286
US
Difelikefalin 1 mg Oral Tablet, CR845, Placebo Oral Tablet
Cara Therapeutics, Inc.
Chronic Kidney Diseases, Pruritus
02/24
02/24
NCT05356403 / 2022-000149-34: CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Terminated
3
105
Europe, US, RoW
Difelikefalin 1 mg Oral Tablet, CR845, Placebo Oral Tablet
Cara Therapeutics, Inc., Cara Therapeutics, Inc.
Chronic Kidney Diseases, Pruritus
02/24
02/24
KIND-1, NCT05387707: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Terminated
3
287
US
difelikefalin 0.25 mg, CR845, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Cara Therapeutics, Inc.
Pruritus, Atopic Dermatitis
02/24
02/24
NCT05978063: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Terminated
2/3
214
Europe, Canada, US
difelikefalin 2.0 mg tablets, CR845, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets, Placebo tablets
Cara Therapeutics, Inc.
Pruritus, Notalgia Paresthetica
04/24
05/24
CKD-386 / Chong Kun Dang
NCT05698043: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Completed
1
63
RoW
CKD-386(5), D013, D326, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
09/23
09/23
Dilatrend SR (carvedilol sustained release) / Chong Kun Dang
PROVE, NCT04345796: Pharmacological Reduction of Right Ventricular Enlargement

Completed
3
56
RoW
Carvedilol+Empagliflozin, Dilatrend SR+Jardiance, Carvedilol, Dilatrend SR, Empagliflozin, Jardiance, Placebo, Matching placebo of Dilatrend SR
Asan Medical Center, Chong Kun Dang Pharmaceutical Corporation
Tricuspid Regurgitation, Right Ventricular Dilatation
06/24
06/24
CKD-333 / Chong Kun Dang
NCT04478097: Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Not yet recruiting
1
51
RoW
CKD-330 Tab. and D086 Tab., Reference, CKD-333 Tab., Test
Chong Kun Dang Pharmaceutical
Cardiovascular Disease
11/20
01/21
CKD-333, NCT04627207: A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of or Co-administration of and D085 in Healthy Volunteers

Not yet recruiting
1
51
NA
CKD-330 1 Tab. and D085 1 Tab., CKD-333 1 Tab
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
03/21
04/21
NCT04611932: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Not yet recruiting
1
51
RoW
CKD-330 Tab. and D090 Tab., Reference, CKD-333 Tab., Test
Chong Kun Dang Pharmaceutical
Cardiovascular Disease
03/21
04/21
CKD-385 / Chong Kun Dang
NCT04651881: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Enrolling by invitation
1
24
RoW
Reference drug, D744, Test drug 1, CKD-385 64 mg formulation I (878mg), Test drug 2, CKD-385 64 mg formulation II (878mg)
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
12/20
12/20
NCT04678388: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Enrolling by invitation
1
24
RoW
Reference drug, D744, Test drug 1, CKD-385 64 mg formulation I (878mg), Test drug 2
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
12/20
12/20
NCT04906798: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Not yet recruiting
1
52
RoW
CKD-385, D744
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
07/21
07/21
NCT04906785: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Not yet recruiting
1
52
RoW
CKD-385, D744
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
07/21
08/21
CKD-387 / Chong Kun Dang
NCT06399055: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions

Completed
1
37
RoW
CKD-387, Test, D484, Reference
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
09/22
10/22
NCT06399068: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions

Completed
1
31
RoW
CKD-387, Test, D484, Reference
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
09/22
10/22
NCT05673369: Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition

Completed
1
40
RoW
CKD-387, Test, D484, Referernce
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
02/23
02/23
CKD-508 / Chong Kun Dang
NCT04488900: Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

Completed
1
88
Europe
CKD-508 Capsule, Placebo Capsule, CKD-508 Tablet, Placebo Tablet
Chong Kun Dang Pharmaceutical
Healthy Subjects
07/23
07/23
NCT06727396: A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

Recruiting
1
40
US
CKD-508 Tablet, Placebo Tablet
Chong Kun Dang Pharmaceutical
Healthy Subjects
05/25
05/25
NCT06979973: A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

Not yet recruiting
1
24
US
Midazolam, Rosuvastatin, CKD-508 Tablet
Chong Kun Dang Pharmaceutical
Healthy
08/25
08/25
CKD-510 / Novartis
NCT05526742: A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

Completed
1
16
US
CKD-510 capsule (reference), CKD-510 tablet (test)
Chong Kun Dang Pharmaceutical
Healthy Volunteers
09/22
09/22
CKD-702 / Chong Kun Dang
NCT05750290: CKD-702 Plus Irinotecan in Gastric Cancer

Recruiting
2
40
RoW
CKD-702 in combination with irinotecan
National Cancer Center, Korea
Gastric Cancer
12/24
12/25
NCT04667975: The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy

Recruiting
1
74
RoW
CKD-702
Chong Kun Dang Pharmaceutical, Seoul National University Hospital, Asan Medical Center, Samsung Medical Center
Non-Small Cell Lung Cancer
08/21
08/24
latanoprost/dorzolamide (CKD-351) / Chong Kun Dang
NCT04448223: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Recruiting
2
100
RoW
CKD-351, Latanoprost+Dorzolmamide
Chong Kun Dang Pharmaceutical
Primary Open Angle Glaucoma, Ocular Hypertension
12/22
12/22
CKD-388 / Chong Kun Dang
NCT04676893: Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

Not yet recruiting
1
56
RoW
D418 Tab., Reference, CKD-388 Tab., Test
Chong Kun Dang Pharmaceutical
Chronic Hepatitis b
05/21
05/21
CKD-382 / Chong Kun Dang
NCT04703374: A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects

Recruiting
1
48
RoW
CKD-382(formulation I), CKD-382(formulation II), D026
Chong Kun Dang Pharmaceutical
GERD
09/21
09/21
NCT05108038: A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

Recruiting
1
42
RoW
CKD-382, D860, D027
Chong Kun Dang Pharmaceutical
GERD
02/22
02/22
CKD-344 / Chong Kun Dang
NCT04673695: A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Recruiting
1
50
RoW
Lixiana(D006), Reference Drug, CKD-344, Test Drug
Chong Kun Dang Pharmaceutical
Anticoagulant
12/20
01/21
NCT04867200: A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Recruiting
1
60
RoW
Lixiana(D006), Reference Drug, CKD-344, Test Drug
Chong Kun Dang Pharmaceutical
Anticoagulant
05/21
06/21
CKD-349 / Chong Kun Dang
NCT04952506: Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers

Completed
1
25
RoW
CKD-349 F1 Tab., Test 1, CKD-349 F2 Tab., Test 2, D113 Tab., Reference
Chong Kun Dang Pharmaceutical
Chronic Renal Failure
07/21
08/21
CKD-331 / Chong Kun Dang
NCT05657574: A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Recruiting
3
228
RoW
D377, CKD-331, D086, Placebo (for D377), Placebo (for CKD-331), Placebo (for D086)
Chong Kun Dang Pharmaceutical
Primary Hypercholesterolemia
06/23
06/23
NCT05335044: Study to Evaluate the Safety and Pharmacokinetics of CKD-331

Completed
1
47
RoW
CKD-331, EX5619
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
06/22
07/22
NCT05634447: A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

Completed
1
69
RoW
Drug: CKD-391, QD, PO
Chong Kun Dang Pharmaceutical
Dyslipidemias
02/23
06/23
NCT06088017: A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Completed
1
66
RoW
CKD-391(2), CKD-331, D337
Chong Kun Dang Pharmaceutical
Dyslipidemias
01/24
01/24
Tyemvers (botulinum toxin type A) / Chong Kun Dang, Cutia Therap
NCT05804656: Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Completed
3
300
RoW
CKDB-501A, Botox®
CKD Bio Corporation
Glabellar Lines
08/23
11/23
NCT06585696: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101)

Recruiting
3
554
RoW
CU-20101 treatment for Moderate to Severe Glabellar Striae
Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Frown Lines
03/26
05/26
NCT05382767: Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

Completed
1
24
RoW
CKDB-501A, Botox®
CKD Bio Corporation
Post-stroke Upper Limb Spasticity
12/22
12/22
empagliflozin/metformin/sitagliptin (CKD-379) / Chong Kun Dang
NCT06952231: Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed
3
50
RoW
Sitagliptin + Metformin, Empagliflozin + Metformin
University of Lahore, University of Lahore Teaching Hospital
Diabetes Mellitus
12/24
01/25
NCT05719155: Pharmacokinetics and Safety/Tolerability of CKD-379

Completed
1
32
RoW
CKD-379, D759+D745+D150
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
03/23
04/23
NCT05952219: Study to Evaluate the Safety and Pharmacokinetics of CKD-379

Active, not recruiting
1
32
RoW
CKD-379, D759+D745+D029+D150
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
06/23
10/23
NCT06204107: A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Completed
1
28
RoW
CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
12/23
12/23
NCT06652971: A Clinical Trial to Evaluate the Food Effect of CKD-379

Completed
1
30
RoW
CKD-379
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
12/24
12/24
CKD-371 / Chong Kun Dang
NCT05544214: Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

Completed
1
32
RoW
CKD-371, D745, D759
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
11/22
11/22
CKD-341 / Chong Kun Dang
NCT05571813: Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects

Completed
1
30
RoW
CKD-341, D958
Chong Kun Dang Pharmaceutical
Hypertension
12/22
12/22
NCT05921435: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults

Completed
1
48
RoW
CKD-341, D958
Chong Kun Dang Pharmaceutical
Hypertension
09/23
09/23
NCT06281132: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults

Completed
1
51
RoW
CKD-341, D956, PO, Tablet
Chong Kun Dang Pharmaceutical
Hypertension
05/24
05/24
CKD-843 / Chong Kun Dang
NCT06916793: A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Not yet recruiting
3
288
RoW
CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose, Dutasteride Capsules, Placebo of Dutasteride Capsule
Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
12/26
09/27
NCT05587699: The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A

Completed
1
41
RoW
CKD-843 A 45mg(Multiple dose), CKD-843 A 45mg, CKD-843 A 55mg(Multiple dose), CKD-843 A 55mg, CKD-843-R
Chong Kun Dang Pharmaceutical
Alopecia
09/23
10/23
CKD-498 / Chong Kun Dang
NCT05677438: A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Completed
2
121
RoW
CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3, Placebo of CKD-498 dose#1, Placebo of CKD-498 dose#2, Placebo of CKD-498 dose#3
Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beloranib (ZGN-440) / Larimar Therap
2015-000660-33: A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placebo

 
3
25
Europe
Subcutaneous Beloranib in Suspension, ZGN-440,
Zafgen Inc., Zafgen Inc.
Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
 
 
Duvie (lobeglitazone) / Chong Kun Dang
NCT02315287: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

Recruiting
4
190
RoW
Pioglitazone, Actos, Lobeglitazone, Duvie
Seoul National University Bundang Hospital
Type 2 Diabetes
12/21
12/21
Location-F, NCT05915949: Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

Recruiting
4
99
RoW
Dapagliflozin 10mg Tab, Forxiga 10mg, Lobeglitazone 0.5 mg, Duvie 0.5 mg, Dapagliflozin + Lobeglitazone, Forxiga 10mg + Duvie 0.5mg
Seoul National University Bundang Hospital
Diabetes Type 2
10/23
12/23
NCT03641352: The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Recruiting
3
240
RoW
CKD-501 0.5mg, Lobeglitazone, Placebo
Chong Kun Dang Pharmaceutical
Type2 Diabetes
04/21
11/22
NCT03627182: Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Recruiting
3
240
RoW
CKD-501 0.5mg, Lobeglitazone 0.5mg, Placebo
Chong Kun Dang Pharmaceutical
Type2 Diabetes
03/22
02/23
NCT04706286: Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

Not yet recruiting
1
26
RoW
CKD-501, D759, D150, Treatment A, CKD-393 0.5/100/1000 mg, Treatment B
Chong Kun Dang Pharmaceutical
T2DM (Type 2 Diabetes Mellitus)
03/21
04/21
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Completed
1
33
RoW
CKD-393, CKD-501, D759, H053
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
12/21
12/21
NCT05816759: Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Completed
1
32
RoW
CKD-383, CKD-501, D744, D150
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
06/23
06/23
NCT05897216: Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

Completed
1
30
RoW
CKD-383, CKD-501, D745, D150, D029
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
07/23
08/23
NCT06483243: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Completed
1
45
RoW
Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG, Test: CKD-383, Reference1: CKD-501, Reference2: D745, Reference3: D150
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
04/24
05/24
NCT06492655: To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

Not yet recruiting
1
28
NA
CKD-383(Fed), Lobeglitazone, Empagliflozin, Metformin, CKD-383(Fasted)
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
08/24
08/24
Tedopi (OSE 2101) / OSE Immunotherapeutics
ATALANTE 1, NCT02654587 / 2015-003183-36: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated
3
219
Europe, US, RoW
OSE2101, TEDOPI, EP-2101, EP2101, IDM-2101, Docetaxel, Taxotere, Pemetrexed, Alimta
OSE Immunotherapeutics, OSE Immunotherapeutics, OSE Pharma
Non Small Cell Lung Cancer
01/21
01/21
ARTEMIA, NCT06472245: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Recruiting
3
363
Europe, Canada, US
OSE2101, Docetaxel, NGS HLAA2 assay
OSE Immunotherapeutics, Exystat, Genome Diagnostics (GenDx)
Patients With Non-Small Cell Lung Cancer
12/27
12/28
2017-004548-40: Phase II randomized of Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with pancreatic carcinoma

Not yet recruiting
2
156
Europe
TEDOPI, nivolumab, OSE2101, Emulsion and suspension for emulsion for injection, Solution for infusion, OPDIVO
GERCOR, OSE IMMUNOTHERAPEUTICS - SA, Bristol Myers Squibb
Locally advanced or metastatic Pancreatic ductal adenocarcinoma, metastatic Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Recruiting
2
105
Europe
Tedopi, Nivolumab, Docetaxel
Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics
Metastatic Non Small Cell Lung Cancer
10/23
05/25
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
2
106
Europe
FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi
GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
12/23
12/24
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
Antiferon (interferon alpha kinoid) / Neovacs
ChiCTR2000035633: Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK/PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients

Not yet recruiting
N/A
32
 
Atomization treatment, 0.2mg IFN-k/ 0.5 mg TFF2 ;Atomization treatment, 1mg IFN-k/ 2.5 mg TFF2 ;Atomization treatment, 2mg IFN-κ/ 5 mg TFF2 ;Atomization treatment, 4mg IFN-κ/ 10 mg TFF2
Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Shanghai Public Health Clinical Center
Novel Coronavirus Pneumonia (COVID-19)
 
 
namodenoson (CF102) / Can-Fite
2021-005286-41: Clinical trial in patients with Advanced Hepatocellular Carcinoma and Child Pugh Class B7 cirrhosis. Клинично изпитване при пациенти с с авансирал хепатоцелуларен карцином с Child-Pugh цироза клас Б7

Ongoing
3
471
Europe
CF102, CF102, Capsule
CanFite BioPharma Ltd., CanFite BioPharma Ltd.
Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis Авансирал хепатоцелуларен карцином с Child-Pugh цироза клас В7, Liver cancer Чернодробен карцином, Diseases [C] - Cancer [C04]
 
 
LIVERATION, NCT05201404 / 2021-005286-41: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Recruiting
3
471
Europe, US, RoW
Namodenoson, CF102, Placebo, Inactive control
Can-Fite BioPharma, CanFite BioPharma Ltd.
Hepatocellular Carcinoma, Cirrhosis
02/26
10/26
CF102-222PC, NCT06387342: Namodenoson Treatment of Advanced Pancreatic Cancer

Recruiting
2
20
RoW
Namodenoson 25mg, CF102
Can-Fite BioPharma
Pancreatic Adenocarcinoma, Pancreatic Cancer
07/26
12/26
NCT04697810 / 2021-005245-32: Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Recruiting
2
114
Europe, RoW
Namodenoson, CF102, Placebo, Inactive control
Can-Fite BioPharma, CanFite BioPharma Ltd.
NASH - Nonalcoholic Steatohepatitis
04/25
10/25
Korsuva IV (difelikefalin IV) / Maruishi Pharma, CSL Behring
NCT04711603: A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Completed
3
178
Japan
MR13A9, Placebo
Kissei Pharmaceutical Co., Ltd.
Uremic Pruritus
01/22
09/22
NCT05885737: Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Completed
3
184
RoW
Difelikefalin Injection, Placebo Injection
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
Uremic Pruritus
09/24
09/24
2021-000894-94: Single dose study to evaluate how intravenous administered difelikefalin is absorbed by and cleared from Adolescents on Haemodialysis Studio a dose singola per valutare come difelikefalin somministrato per via endovenosa viene assorbito ed eliminato dagli adolescenti in emodialisi

Ongoing
2
6
Europe
Difelikefalin, [CR845], Solution for infusion
Vifor Fresenius Medical Care Renal Pharma Ltd., Vifor Fresenius Medical Care Renal Pharma Ltd.
Renal disease in the final stage Nefropatia allo stadio terminale, Renal disease in the final stage Malattia renale allo stadio terminale, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Recruiting
2
18
Europe
Difelikefalin
Vifor Fresenius Medical Care Renal Pharma
Pruritus, Chronic Kidney Diseases
08/29
08/29
NCT05885763: Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis

Completed
1
30
RoW
Difelikefalin Injection
Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd
End Stage Renal Disease on Hemodialysis
10/23
10/23
alteminostat (CKD-581) / Chong Kun Dang
NCT03051841: CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Recruiting
1
18
RoW
CKD-581, CKD-581 bortezomib dexamethasone regimen
Chong Kun Dang Pharmaceutical
Myeloma, Multiple
04/21
11/22
valecobulin (CKD-516) / Chong Kun Dang
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Terminated
1/2
25
RoW
CKD-516 plus Durvalumab, CKD-516 plus MEDI4736
Tae Won Kim
Colorectal Cancer, Solid Tumor
03/23
03/23
leuprorelin (CKD-841) / Chong Kun Dang
NCT04840745: The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

Not yet recruiting
1
32
RoW
CKD-841 A-1 3.75mg, CKD-841, CKD-841 A-1 1.88mg, CKD-841 D 2.92mg, Leuplin Inj. 3.75 mg, Leuplin.Inj
Chong Kun Dang Pharmaceutical, Severance Hospital
Early Puberty
10/21
11/21
Telmunivo (s-amlidioine / telmisartan) / Chong Kun Dang
CKD-348, NCT04660370: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of

Completed
1
70
RoW
CKD-348, CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
02/21
04/21
NCT04883658: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Completed
1
62
RoW
CKD-348(2), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
07/21
08/21
NCT05192356: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Completed
1
63
RoW
CKD-348(3), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
05/22
06/22
NCT05549401: Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Completed
1
32
RoW
CKD-348(4) F1, CKD-348(4) F2, CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
11/22
12/22
NCT05749861: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Completed
1
65
RoW
CKD-348(5), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
06/23
07/23
NCT05834595: A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828

Completed
1
43
RoW
CKD-828, D064, D701
Chong Kun Dang Pharmaceutical
Hypertension
07/23
07/23
NCT05881707: A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg

Completed
1
44
RoW
CKD-828, D064, D702
Chong Kun Dang Pharmaceutical
Hypertension
09/23
09/23
NCT06112678: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Completed
1
63
RoW
CKD-348(6), CKD-828, D097, D337
Chong Kun Dang Pharmaceutical
Hypertension, Dyslipidemias
02/24
03/24
CKD-506 / Chong Kun Dang
2018-001377-24: Not available.

Not yet recruiting
2
120
RoW
CKD-506, Tablet
Chong Kun Dang Pharmaceutical Corporation (CKD), Chong Kun Dang Pharmaceutical Corporation (CKD)
Rheumatoid arthritis (RA), Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
Korsuva oral (difelikefalin oral) / CSL Behring
2022-000149-34: A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extension

Not yet recruiting
3
400
Europe, RoW
Difelikefalin, CR845, Tablet
Cara Therapeutics, Inc., Cara Therapeutics, Inc,, Cara Therapeutics, Inc.
Chronic Kidney Disease, Chronic Kidney Disease, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05342623: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Checkmark Trial initiation in non-hemodialysis CKD-aP patients
Apr 2022 - Apr 2022: Trial initiation in non-hemodialysis CKD-aP patients
Terminated
3
286
US
Difelikefalin 1 mg Oral Tablet, CR845, Placebo Oral Tablet
Cara Therapeutics, Inc.
Chronic Kidney Diseases, Pruritus
02/24
02/24
NCT05356403 / 2022-000149-34: CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Terminated
3
105
Europe, US, RoW
Difelikefalin 1 mg Oral Tablet, CR845, Placebo Oral Tablet
Cara Therapeutics, Inc., Cara Therapeutics, Inc.
Chronic Kidney Diseases, Pruritus
02/24
02/24
KIND-1, NCT05387707: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Terminated
3
287
US
difelikefalin 0.25 mg, CR845, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Cara Therapeutics, Inc.
Pruritus, Atopic Dermatitis
02/24
02/24
NCT05978063: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Terminated
2/3
214
Europe, Canada, US
difelikefalin 2.0 mg tablets, CR845, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets, Placebo tablets
Cara Therapeutics, Inc.
Pruritus, Notalgia Paresthetica
04/24
05/24
CKD-386 / Chong Kun Dang
NCT05698043: A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Completed
1
63
RoW
CKD-386(5), D013, D326, D337
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
09/23
09/23
Dilatrend SR (carvedilol sustained release) / Chong Kun Dang
PROVE, NCT04345796: Pharmacological Reduction of Right Ventricular Enlargement

Completed
3
56
RoW
Carvedilol+Empagliflozin, Dilatrend SR+Jardiance, Carvedilol, Dilatrend SR, Empagliflozin, Jardiance, Placebo, Matching placebo of Dilatrend SR
Asan Medical Center, Chong Kun Dang Pharmaceutical Corporation
Tricuspid Regurgitation, Right Ventricular Dilatation
06/24
06/24
CKD-333 / Chong Kun Dang
NCT04478097: Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Not yet recruiting
1
51
RoW
CKD-330 Tab. and D086 Tab., Reference, CKD-333 Tab., Test
Chong Kun Dang Pharmaceutical
Cardiovascular Disease
11/20
01/21
CKD-333, NCT04627207: A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of or Co-administration of and D085 in Healthy Volunteers

Not yet recruiting
1
51
NA
CKD-330 1 Tab. and D085 1 Tab., CKD-333 1 Tab
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
03/21
04/21
NCT04611932: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Not yet recruiting
1
51
RoW
CKD-330 Tab. and D090 Tab., Reference, CKD-333 Tab., Test
Chong Kun Dang Pharmaceutical
Cardiovascular Disease
03/21
04/21
CKD-385 / Chong Kun Dang
NCT04651881: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Enrolling by invitation
1
24
RoW
Reference drug, D744, Test drug 1, CKD-385 64 mg formulation I (878mg), Test drug 2, CKD-385 64 mg formulation II (878mg)
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
12/20
12/20
NCT04678388: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Enrolling by invitation
1
24
RoW
Reference drug, D744, Test drug 1, CKD-385 64 mg formulation I (878mg), Test drug 2
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
12/20
12/20
NCT04906798: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Not yet recruiting
1
52
RoW
CKD-385, D744
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
07/21
07/21
NCT04906785: Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Not yet recruiting
1
52
RoW
CKD-385, D744
Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
07/21
08/21
CKD-387 / Chong Kun Dang
NCT06399055: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions

Completed
1
37
RoW
CKD-387, Test, D484, Reference
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
09/22
10/22
NCT06399068: Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions

Completed
1
31
RoW
CKD-387, Test, D484, Reference
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
09/22
10/22
NCT05673369: Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition

Completed
1
40
RoW
CKD-387, Test, D484, Referernce
Chong Kun Dang Pharmaceutical
Endocrine, Nutritional and Metabolic Diseases
02/23
02/23
CKD-508 / Chong Kun Dang
NCT04488900: Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

Completed
1
88
Europe
CKD-508 Capsule, Placebo Capsule, CKD-508 Tablet, Placebo Tablet
Chong Kun Dang Pharmaceutical
Healthy Subjects
07/23
07/23
NCT06727396: A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

Recruiting
1
40
US
CKD-508 Tablet, Placebo Tablet
Chong Kun Dang Pharmaceutical
Healthy Subjects
05/25
05/25
NCT06979973: A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

Not yet recruiting
1
24
US
Midazolam, Rosuvastatin, CKD-508 Tablet
Chong Kun Dang Pharmaceutical
Healthy
08/25
08/25
CKD-510 / Novartis
NCT05526742: A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

Completed
1
16
US
CKD-510 capsule (reference), CKD-510 tablet (test)
Chong Kun Dang Pharmaceutical
Healthy Volunteers
09/22
09/22
CKD-702 / Chong Kun Dang
NCT05750290: CKD-702 Plus Irinotecan in Gastric Cancer

Recruiting
2
40
RoW
CKD-702 in combination with irinotecan
National Cancer Center, Korea
Gastric Cancer
12/24
12/25
NCT04667975: The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy

Recruiting
1
74
RoW
CKD-702
Chong Kun Dang Pharmaceutical, Seoul National University Hospital, Asan Medical Center, Samsung Medical Center
Non-Small Cell Lung Cancer
08/21
08/24
latanoprost/dorzolamide (CKD-351) / Chong Kun Dang
NCT04448223: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Recruiting
2
100
RoW
CKD-351, Latanoprost+Dorzolmamide
Chong Kun Dang Pharmaceutical
Primary Open Angle Glaucoma, Ocular Hypertension
12/22
12/22
CKD-388 / Chong Kun Dang
NCT04676893: Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

Not yet recruiting
1
56
RoW
D418 Tab., Reference, CKD-388 Tab., Test
Chong Kun Dang Pharmaceutical
Chronic Hepatitis b
05/21
05/21
CKD-382 / Chong Kun Dang
NCT04703374: A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects

Recruiting
1
48
RoW
CKD-382(formulation I), CKD-382(formulation II), D026
Chong Kun Dang Pharmaceutical
GERD
09/21
09/21
NCT05108038: A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

Recruiting
1
42
RoW
CKD-382, D860, D027
Chong Kun Dang Pharmaceutical
GERD
02/22
02/22
CKD-344 / Chong Kun Dang
NCT04673695: A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Recruiting
1
50
RoW
Lixiana(D006), Reference Drug, CKD-344, Test Drug
Chong Kun Dang Pharmaceutical
Anticoagulant
12/20
01/21
NCT04867200: A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Recruiting
1
60
RoW
Lixiana(D006), Reference Drug, CKD-344, Test Drug
Chong Kun Dang Pharmaceutical
Anticoagulant
05/21
06/21
CKD-349 / Chong Kun Dang
NCT04952506: Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers

Completed
1
25
RoW
CKD-349 F1 Tab., Test 1, CKD-349 F2 Tab., Test 2, D113 Tab., Reference
Chong Kun Dang Pharmaceutical
Chronic Renal Failure
07/21
08/21
CKD-331 / Chong Kun Dang
NCT05657574: A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Recruiting
3
228
RoW
D377, CKD-331, D086, Placebo (for D377), Placebo (for CKD-331), Placebo (for D086)
Chong Kun Dang Pharmaceutical
Primary Hypercholesterolemia
06/23
06/23
NCT05335044: Study to Evaluate the Safety and Pharmacokinetics of CKD-331

Completed
1
47
RoW
CKD-331, EX5619
Chong Kun Dang Pharmaceutical
Hypertension and Dyslipidemia
06/22
07/22
NCT05634447: A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

Completed
1
69
RoW
Drug: CKD-391, QD, PO
Chong Kun Dang Pharmaceutical
Dyslipidemias
02/23
06/23
NCT06088017: A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Completed
1
66
RoW
CKD-391(2), CKD-331, D337
Chong Kun Dang Pharmaceutical
Dyslipidemias
01/24
01/24
Tyemvers (botulinum toxin type A) / Chong Kun Dang, Cutia Therap
NCT05804656: Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Completed
3
300
RoW
CKDB-501A, Botox®
CKD Bio Corporation
Glabellar Lines
08/23
11/23
NCT06585696: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101)

Recruiting
3
554
RoW
CU-20101 treatment for Moderate to Severe Glabellar Striae
Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Frown Lines
03/26
05/26
NCT05382767: Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

Completed
1
24
RoW
CKDB-501A, Botox®
CKD Bio Corporation
Post-stroke Upper Limb Spasticity
12/22
12/22
empagliflozin/metformin/sitagliptin (CKD-379) / Chong Kun Dang
NCT06952231: Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed
3
50
RoW
Sitagliptin + Metformin, Empagliflozin + Metformin
University of Lahore, University of Lahore Teaching Hospital
Diabetes Mellitus
12/24
01/25
NCT05719155: Pharmacokinetics and Safety/Tolerability of CKD-379

Completed
1
32
RoW
CKD-379, D759+D745+D150
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
03/23
04/23
NCT05952219: Study to Evaluate the Safety and Pharmacokinetics of CKD-379

Active, not recruiting
1
32
RoW
CKD-379, D759+D745+D029+D150
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
06/23
10/23
NCT06204107: A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Completed
1
28
RoW
CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
12/23
12/23
NCT06652971: A Clinical Trial to Evaluate the Food Effect of CKD-379

Completed
1
30
RoW
CKD-379
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
12/24
12/24
CKD-371 / Chong Kun Dang
NCT05544214: Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects

Completed
1
32
RoW
CKD-371, D745, D759
Chong Kun Dang Pharmaceutical
Type II Diabetes Mellitus
11/22
11/22
CKD-341 / Chong Kun Dang
NCT05571813: Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects

Completed
1
30
RoW
CKD-341, D958
Chong Kun Dang Pharmaceutical
Hypertension
12/22
12/22
NCT05921435: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D958 in Healthy Adults

Completed
1
48
RoW
CKD-341, D958
Chong Kun Dang Pharmaceutical
Hypertension
09/23
09/23
NCT06281132: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults

Completed
1
51
RoW
CKD-341, D956, PO, Tablet
Chong Kun Dang Pharmaceutical
Hypertension
05/24
05/24
CKD-843 / Chong Kun Dang
NCT06916793: A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Not yet recruiting
3
288
RoW
CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose, Dutasteride Capsules, Placebo of Dutasteride Capsule
Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
12/26
09/27
NCT05587699: The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A

Completed
1
41
RoW
CKD-843 A 45mg(Multiple dose), CKD-843 A 45mg, CKD-843 A 55mg(Multiple dose), CKD-843 A 55mg, CKD-843-R
Chong Kun Dang Pharmaceutical
Alopecia
09/23
10/23
CKD-498 / Chong Kun Dang
NCT05677438: A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Completed
2
121
RoW
CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3, Placebo of CKD-498 dose#1, Placebo of CKD-498 dose#2, Placebo of CKD-498 dose#3
Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
12/23
12/23

Download Options